Renovaro (RENB) said Wednesday it agreed to a merger with artificial intelligence-driven drug discovery company BioSymetrics.
Financial terms of the transaction were not disclosed.
The company said it expects to close the transaction in March, with the combined company integrating BioSymetrics' Elion platform into Renovaro's workflow.
Shares of Renovaro were up more than 35% in recent trading.
Price: 1.05, Change: +0.27, Percent Change: +35.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.